{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:25:23Z","timestamp":1787444723318,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"42","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA177865"],"award-info":[{"award-number":["R21CA177865"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA154387"],"award-info":[{"award-number":["R01CA154387"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA136393"],"award-info":[{"award-number":["P50CA136393"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,10,15]]},"DOI":"10.1038\/s41388-020-01451-4","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T09:03:36Z","timestamp":1600074216000},"page":"6606-6618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Targeting an autocrine IL-6\u2013SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma"],"prefix":"10.1038","volume":"39","author":[{"given":"Christine","family":"Mehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hockla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-6759","authenticated-orcid":false,"given":"Mathew","family":"Coban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek C.","family":"Radisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-109X","authenticated-orcid":false,"given":"Evette S.","family":"Radisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"1451_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975\u20132016. Bethesda, MD: National Cancer Institute; 2017."},{"key":"1451_CR2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian Cancer Development and Metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"1451_CR3","doi-asserted-by":"crossref","unstructured":"Mitra AK. Ovarian cancer metastasis: a unique mechanism of dissemination. In: Xu K (editor). Tumor metastasis. Rijeka: InTech; 2016.","DOI":"10.5772\/64700"},{"key":"1451_CR4","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck H-J, Meier W, Adams H-P, M\u00f6bus V, Costa S, et al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1451_CR5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584\u20139.","journal-title":"Cancer"},{"key":"1451_CR6","doi-asserted-by":"crossref","unstructured":"Takano M, Kikuchi Y, Yaegashi N. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369\u201374.","DOI":"10.1038\/sj.bjc.6603116"},{"key":"1451_CR7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","volume":"126","author":"MG del Carmen","year":"2012","unstructured":"del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecologic Oncol. 2012;126:481\u201390.","journal-title":"Gynecologic Oncol"},{"key":"1451_CR8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncol. 2008;109:370\u20136.","journal-title":"Gynecologic Oncol"},{"key":"1451_CR9","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","volume":"3","author":"N Ahmed","year":"2013","unstructured":"Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.","journal-title":"Front Oncol"},{"key":"1451_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.029","volume":"272","author":"CD Simpson","year":"2008","unstructured":"Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272:177\u201385.","journal-title":"Cancer Lett"},{"key":"1451_CR11","doi-asserted-by":"crossref","first-page":"35737","DOI":"10.18632\/oncotarget.5927","volume":"6","author":"C Mehner","year":"2015","unstructured":"Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 2015;6:35737\u201354.","journal-title":"Oncotarget"},{"key":"1451_CR12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/BF01318124","volume":"31","author":"H Rinderknecht","year":"1986","unstructured":"Rinderknecht H. Activation of pancreatic zymogens. Normal activation, premature intrapancreatic activation, protective mechanisms against inappropriate activation. Dig Dis Sci (Rev). 1986;31:314\u201321.","journal-title":"Dig Dis Sci (Rev)"},{"key":"1451_CR13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2014.02.014","volume":"431","author":"O Itkonen","year":"2014","unstructured":"Itkonen O, Stenman UH. TATI as a biomarker. Clin Chim Acta; Int J Clin Chem. 2014;431:260\u20139.","journal-title":"Clin Chim Acta; Int J Clin Chem"},{"key":"1451_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1373\/clinchem.2015.241513","volume":"62","author":"K Rasanen","year":"2016","unstructured":"Rasanen K, Itkonen O, Koistinen H, Stenman UH. Emerging roles of SPINK1 in cancer. Clin Chem. 2016;62:449\u201357.","journal-title":"Clin Chem"},{"key":"1451_CR15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/aja.2011.45","volume":"13","author":"UH Stenman","year":"2011","unstructured":"Stenman UH. Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development. Asian J Androl. 2011;13:628\u20139.","journal-title":"Asian J Androl"},{"key":"1451_CR16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol (Rev). 2015;16:448\u201357.","journal-title":"Nat Immunol (Rev)"},{"key":"1451_CR17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.smim.2014.01.001","volume":"26","author":"K Taniguchi","year":"2014","unstructured":"Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54\u201374.","journal-title":"Semin Immunol"},{"issue":"Suppl","key":"1451_CR18","first-page":"95","volume":"371","author":"T Yasuda","year":"1990","unstructured":"Yasuda T, Ogawa M, Murata A, Oka Y, Uda K, Mori T. Response to IL-6 stimulation of human hepatoblastoma cells: production of pancreatic secretory trypsin inhibitor. Biol Chem Hoppe Seyler. 1990;371(Suppl):95\u2013100.","journal-title":"Biol Chem Hoppe Seyler"},{"key":"1451_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-1119(93)90306-N","volume":"131","author":"T Yasuda","year":"1993","unstructured":"Yasuda T, Ogawa M, Murata A, Ohmachi Y, Yasuda T, Mori T, et al. Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene. Gene. 1993;131:275\u201380.","journal-title":"Gene"},{"key":"1451_CR20","doi-asserted-by":"crossref","unstructured":"Rasanen K, Lehtinen E, Nokelainen K, Kuopio T, Hautala L, Itkonen O, et al. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma. Mol Carcinog. 2016;55:2010\u201323.","DOI":"10.1002\/mc.22447"},{"key":"1451_CR21","first-page":"6959","volume":"50","author":"JM Watson","year":"1990","unstructured":"Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990;50:6959\u201365.","journal-title":"Cancer Res"},{"key":"1451_CR22","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1158\/0008-5472.CAN-05-0623","volume":"65","author":"MB Nilsson","year":"2005","unstructured":"Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005;65:10794\u2013800.","journal-title":"Cancer Res"},{"key":"1451_CR23","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","volume":"17","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17:2538\u201348.","journal-title":"Clin Cancer Res"},{"key":"1451_CR24","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7118","volume":"6","author":"RL Chandler","year":"2015","unstructured":"Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, et al. Coexistent ARID1A\u2013PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. 2015;6:6118.","journal-title":"Nat Commun"},{"key":"1451_CR25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ygyno.2017.06.027","volume":"146","author":"A Kawabata","year":"2017","unstructured":"Kawabata A, Yanaihara N, Nagata C, Saito M, Noguchi D, Takenaka M, et al. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. Gynecologic Oncol. 2017;146:609\u201314.","journal-title":"Gynecologic Oncol"},{"key":"1451_CR26","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/mc.22325","volume":"55","author":"N Yanaihara","year":"2016","unstructured":"Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, et al. Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. 2016;55:832\u201341.","journal-title":"Mol Carcinog"},{"key":"1451_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021121","volume":"6","author":"MP Stany","year":"2011","unstructured":"Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE. 2011;6:e21121.","journal-title":"PLoS ONE"},{"key":"1451_CR28","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1002\/jcp.27407","volume":"234","author":"L Yuniati","year":"2019","unstructured":"Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: Beyond growth control. J Cell Physiol. 2019;234:5379\u201389.","journal-title":"J Cell Physiol"},{"key":"1451_CR29","first-page":"893","volume":"38","author":"G Hirano","year":"2011","unstructured":"Hirano G, Izumi H, Yasuniwa Y, Shimajiri S, Ke-Yong W, Sasagiri Y, et al. Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. Int J Oncol. 2011;38:893\u2013902.","journal-title":"Int J Oncol"},{"key":"1451_CR30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/emmm.201202341","volume":"5","author":"D Cepeda","year":"2013","unstructured":"Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. 2013;5:1067\u201386.","journal-title":"EMBO Mol Med"},{"key":"1451_CR31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fcell.2018.00162","volume":"6","author":"K Marzec","year":"2018","unstructured":"Marzec K, Burgess A. The oncogenic functions of MASTL kinase. Front Cell Dev Biol. 2018;6:162","journal-title":"Front Cell Dev Biol"},{"key":"1451_CR32","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/clinchem\/48.8.1206","volume":"48","author":"U-H Stenman","year":"2002","unstructured":"Stenman U-H. Tumor-associated trypsin inhibitor. Clin Chem. 2002;48:1206\u20139.","journal-title":"Clin Chem"},{"key":"1451_CR33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ccr.2008.04.016","volume":"13","author":"SA Tomlins","year":"2008","unstructured":"Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008;13:519\u201328.","journal-title":"Cancer Cell"},{"key":"1451_CR34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/emmm.201100150","volume":"3","author":"WW Soon","year":"2011","unstructured":"Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, et al. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med. 2011;3:451\u201364.","journal-title":"EMBO Mol Med"},{"key":"1451_CR35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1987.175","volume":"56","author":"H Halila","year":"1987","unstructured":"Halila H, Huhtala ML, Haglund C, Nordling S, Stenman UH. Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer. 1987;56:153\u20136.","journal-title":"Br J Cancer"},{"key":"1451_CR36","doi-asserted-by":"crossref","first-page":"13713","DOI":"10.1016\/S0021-9258(18)33505-1","volume":"257","author":"ML Huhtala","year":"1982","unstructured":"Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem. 1982;257:13713\u20136.","journal-title":"J Biol Chem"},{"key":"1451_CR37","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-0204-03","volume":"10","author":"A Paju","year":"2004","unstructured":"Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004;10:4761\u20138.","journal-title":"Clin Cancer Res"},{"key":"1451_CR38","doi-asserted-by":"crossref","first-page":"72ra17","DOI":"10.1126\/scitranslmed.3001498","volume":"3","author":"B Ateeq","year":"2011","unstructured":"Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med. 2011;3:72ra17.","journal-title":"Sci Transl Med"},{"key":"1451_CR39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/JVI.01249-09","volume":"84","author":"J Lamontagne","year":"2010","unstructured":"Lamontagne J, Pinkerton M, Block TM, Lu X, Hepatitis B, Hepatitis C. Virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol. 2010;84:907\u201317.","journal-title":"J Virol"},{"key":"1451_CR40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10495-008-0193-x","volume":"13","author":"X Lu","year":"2008","unstructured":"Lu X, Lamontagne J, Lu F, Block TM. Tumor-associated protein SPIK\/TATI suppresses serine protease dependent cell apoptosis. Apoptosis: Int J Program Cell Death. 2008;13:483\u201394.","journal-title":"Apoptosis: Int J Program Cell Death"},{"key":"1451_CR41","volume":"9","author":"F Chen","year":"2018","unstructured":"Chen F, Long Q, Fu D, Zhu D, Ji Y, Han L, et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance. Nat Commun. 2018;9:4315.","journal-title":"Nat Commun"},{"key":"1451_CR42","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532\u201343.","journal-title":"N Engl J Med"},{"key":"1451_CR43","doi-asserted-by":"crossref","unstructured":"Sugiyama T, Yakushiji M, Nishida T. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998;128:211\u20138.","DOI":"10.1016\/S0304-3835(98)00065-2"},{"key":"1451_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/856f0890-9d85-4719-8e54-c27530ac94f4","volume":"8","author":"MS Anglesio","year":"2013","unstructured":"Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE. 2013;8:e72162.","journal-title":"PLoS ONE"},{"key":"1451_CR45","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol: Off J Eur Soc Med Oncol. 2015;26:2141\u20139.","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"1451_CR46","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","volume":"17","author":"J Coward","year":"2011","unstructured":"Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res. 2011;17:6083\u201396.","journal-title":"Clin Cancer Res"},{"key":"1451_CR47","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, et al. A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:2192\u2013204.","journal-title":"Clin Cancer Res"},{"key":"1451_CR48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1634\/theoncologist.11-10-1089","volume":"11","author":"D Pectasides","year":"2006","unstructured":"Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? oncologist. 2006;11:1089\u201394.","journal-title":"oncologist"},{"key":"1451_CR49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"1451_CR50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/1078155213506244","volume":"20","author":"OM Al-Quteimat","year":"2014","unstructured":"Al-Quteimat OM, Al-Badaineh MA. Intraperitoneal chemotherapy: rationale, applications, and limitations. J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract. 2014;20:369\u201380.","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract"},{"key":"1451_CR51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/gut.2008.164947","volume":"58","author":"E Kereszturi","year":"2009","unstructured":"Kereszturi E, Kiraly O, Sahin-Toth M. Minigene analysis of intronic variants in common SPINK1 haplotypes associated with chronic pancreatitis. Gut. 2009;58:545\u20139.","journal-title":"Gut"},{"key":"1451_CR52","doi-asserted-by":"crossref","unstructured":"Portolano N, Watson PJ, Fairall L, Millard CJ, Milano CP, Song Y, et al. Recombinant protein expression for structural biology in HEK 293F suspension cells: a novel and accessible approach. J Vis Exp. 2014;92:e51897.","DOI":"10.3791\/51897"},{"key":"1451_CR53","first-page":"1","volume":"14","author":"MA Cichon","year":"2015","unstructured":"Cichon MA, Nelson CM, Radisky DC. Regulation of epithelial-mesenchymal transition in breast cancer cells by cell contact and adhesion. Cancer Inf. 2015;14:1\u201313.","journal-title":"Cancer Inf"},{"key":"1451_CR54","volume":"9","author":"H Ma","year":"2019","unstructured":"Ma H, Hockla A, Mehner C, Coban M, Papo N, Radisky DC, et al. PRSS3\/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma. Sci Rep. 2019;9:1844.","journal-title":"Sci Rep"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01451-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T23:19:49Z","timestamp":1631575189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-01451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":54,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2020,10,15]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-01451-4","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"3 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}